Full-Time

Director – Regulatory Affairs

Confirmed live in the last 24 hours

Umoja Biopharma

Umoja Biopharma

51-200 employees

Develops in vivo CAR T-cell therapies

Biotechnology
Healthcare

Compensation Overview

$195.5k - $237kAnnually

Senior

Seattle, WA, USA

Preference for candidates in the Seattle area.

Category
Risk & Compliance
Legal & Compliance
Requirements
  • BS/BA degree (or equivalent) in a relevant scientific field required; advanced degree (MS or PhD) is preferred.
  • A minimum of 10 years of experience in regulatory affairs with a focus on regulatory documentation and lifecycle management within the pharmaceutical or biotechnology industry is a must, including 3 years of experience in management/leadership roles.
  • Experience with oncology products
  • Knowledge of regulatory requirements across development stages and post-approval is essential. Experience with regulations for:
  • Biologics and/or small molecules required
  • Cell/gene therapy desired.
  • Combination products desired
  • Expert working knowledge of full drug development process and knowledge of FDA and ICH regulatory requirements
  • Strong strategic and analytical abilities, diplomacy, and negotiation skills
  • Ability to collaboratively influence across multiple functions, and motivate others to accomplish company objectives
  • Ability to work flexibly within tight timelines and with strong project management skills
  • Self-motivated and detail oriented with sound judgement and innovative thinking to deal with challenges/opportunities.
Responsibilities
  • Independently provide effective phase-appropriate strategic guidance/input related to current regulatory requirements and expectations for clinical trial applications and marketing applications for development projects
  • Plan, prepare, and manage submissions to HAs including DMFs, INDs, NDA/BLA and CTD regulatory filings
  • Lead regulatory interactions with HAs including managing preparation of briefing materials for HA meetings, preparing subject matter experts (SMEs), and ensuring appropriate follow-up.
  • Work in close collaboration with consultants and/or CROs, as needed, to ensure appropriate interactions with HAs.
  • Utilize various electronic systems for dossier creation and tracking
  • Represent the regulatory function on cross-functional product development teams and provide innovative strategic and tactical advice to achieve timely and efficient development and maintenance of programs, while ensuring compliance with applicable regulatory requirements
  • Effectively communicate the regulatory strategy, risks, mitigations and overall plans to Regulatory Affairs, program teams, senior management, and external stakeholders (as relevant)
  • Identify, communicate, and propose resolutions to both routine and complex issues
  • Deliver clear and engaging presentations to internal teams and senior management
  • Remain current on Regulatory Intelligence, new guidance documents and competitive information to provide comprehensive information to program teams
  • Support or lead non-project activities, as needed such as SOP/standards development

Umoja Biopharma focuses on immunotherapy by reprogramming T cells in the body to target and destroy cancer cells. Unlike traditional methods that modify cells outside the body, Umoja's approach modifies the immune system in vivo, aiming for long-lasting remissions. The company primarily targets patients with solid tumors and hematological cancers that have not responded to existing treatments. Its business model is based on developing and commercializing a proprietary CAR T-cell gene therapy platform that is scalable and can treat cancers at various stages. By producing off-the-shelf therapies in-house, Umoja can distribute its treatments more efficiently than those requiring individual customization. The goal is to enhance cancer treatment through effective use of the immune system.

Company Stage

Series B

Total Funding

$255.8M

Headquarters

Seattle, Washington

Founded

2019

Growth & Insights
Headcount

6 month growth

3%

1 year growth

12%

2 year growth

45%
Simplify Jobs

Simplify's Take

What believers are saying

  • The collaboration with AbbVie, valued at up to $1.44 billion, provides substantial financial backing and validation of Umoja's technology.
  • Umoja's appointment of experienced executives like Britton Russell as CFO indicates strong leadership capable of guiding the company through growth phases.
  • Being recognized as one of the thriving biotechs in Seattle underscores Umoja's prominence and potential in the biotech industry.

What critics are saying

  • The success of Umoja's in vivo CAR T-cell therapies is still contingent on clinical trial outcomes, which carry inherent uncertainties.
  • The competitive landscape in immunotherapy is intense, with numerous companies vying for market share, which could impact Umoja's growth.

What makes Umoja Biopharma unique

  • Umoja Biopharma's in vivo approach to reprogramming T cells is a significant departure from traditional ex vivo methods, offering a potentially more efficient and scalable solution.
  • Their proprietary CAR T-cell gene therapy platform is designed to be off-the-shelf, allowing for faster production and distribution compared to customized therapies.
  • Strategic partnerships with major players like AbbVie highlight Umoja's innovative edge and potential for significant market impact.

Help us improve and share your feedback! Did you find this helpful?